HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil hcaplu
FILE 'HCAPLUS' ENTERED AT 13:45:54 ON 20 MAR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Mar 2002 VOL 136 ISS 12
FILE LAST UPDATED: 18 Mar 2002 (20020318/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

The P indicator for Preparations was not generated for all of the CAS Registry Numbers that were added to the CAS files between 12/27/01 and 1/23/02. As of 1/23/02, the situation has been resolved. Searches and/or SDIs in the H/Z/CA/CAplus files incorporating CAS Registry Numbers with the P indicator executed between 12/27/01 and 1/23/02 may be incomplete. See the NEWS message on this topic for more information.

=> d stat que
L1 423 SEA FILE=REGISTRY HEPARIN?/CN
L2 1449 SEA FILE=REGISTRY INOSITOL?/CN
L3 52262 SEA FILE=HCAPLUS L1 OR HEPARIN?
L4 38830 SEA FILE=HCAPLUS L2 OR INOSITOL?
L5 994 SEA FILE=HCAPLUS (L3 OR L4) AND POLYACRYLAMIDE?
L7 10 SEA FILE=HCAPLUS (WOUND? OR DRESSING?) AND L5

=> d ibib abs hitrn l7 1-10

L7 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:187305 HCAPLUS
TITLE: Preparation of O-hexanoyl **heparin** oligosaccharides
AUTHOR(S): Butler, Melissa N.; Islam, Tasneem; Linhardt, Robert
CORPORATE SOURCE: Department of Chemistry, Loras College, Dubuque, IA,

52001, USA
SOURCE: Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL, United States, April 7-11, 2002 (2002), CHED-674. American Chemical Society: Washington, D. C.
CODEN: 69CKQP
DOCUMENT TYPE: Conference; Meeting Abstract
LANGUAGE: English
AB **Heparin** has many clin. applications and has been used as an anticoagulant since 1939. Previous research suggests that the hexanoyl deriv. of **heparin** fragments may help to prevent scarring. For this research, O-hexanoyl **heparin** oligosaccharides were prepd. to assist research being done on scarless **wound** healing. First, the periodate-oxidized **heparin** fragments were prepd., and **polyacrylamide** gel electrophoresis was used for verification. Then the tributylammonium salt of the periodate-oxidized **heparin** fragments was prepd. Finally, the o-hexanoyl deriv. of the periodate-oxidized **heparin** fragments was prepd. Proton NMR was used to det. that the desired product was prepd. This product will be tested on pigs to see if it does in fact help to prevent scarring.

L7 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:809084 HCAPLUS
DOCUMENT NUMBER: 135:348912
TITLE: Pectic substance as a growth factor stabilizer
INVENTOR(S): Ni, Yawei; Yates, Kenneth M.
PATENT ASSIGNEE(S): Carrington Laboratories, Inc., USA
SOURCE: U.S., 18 pp., Cont.-in-part of U.S. 5,929,051.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6313103	B1	20011106	US 1998-122010	19980724
US 5929051	A	19990727	US 1998-78204	19980513
WO 2000005257	A1	20000203	WO 1999-US11133	19990520
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9940064	A1	20000214	AU 1999-40064	19990520
EP 1100820	A1	20010523	EP 1999-923246	19990520
R: BE, DE, FR, GB, IT, SE				
US 6274548	B1	20010814	US 1999-325923	19990604

PRIORITY APPLN. INFO.: US 1998-78204 A2 19980513
US 1998-122010 A 19980724

WO 1999-US11133 W 19990520

AB Pectic substance from Aloe vera and other sources is used as a stabilizer and a delivery vehicle for pectin/**heparin**-binding proteins, such as pectin/**heparin** binding growth factors. Aloe pectin, a naturally occurring LM (low methoxyl) pectin, binds to pectin/**heparin**-binding growth factors, i.e., bFGF, aFGF, and KGF of fibroblast growth factor (FGF) family and TGF-.beta.1 of transforming growth factor-.beta. (TGF-.beta.) family. Com. LM or HM (high methoxyl) citrus pectins tested did not exhibit any binding activity with bFGF. A weak binding to bFGF was obsd. with a de-esterified pectin (polygalacturonic acid) prepd. from citrus. The binding protected the growth factor from protease digestion. The calcium gel beads prepd. with Aloe pectin also bound to these pectin/**heparin**-binding growth factors. The growth factor could also be encapsulated in the pectin calcium gel and Aloe pectin sodium gel. Pectin/**heparin**-binding growth factor stabilized by pectin is used for **wound** healing. A pectin-contg. matrix is used for the isolation of a pectin/**heparin**-binding protein. For example, a pharmaceutical formulation of a pectin/**heparin**-binding growth factor can be made by mixing and blending the following ingredients: (i) a pectic substance 0.001-40 mg/mL, (ii) a pectin/**heparin**-binding growth factor (PHBGF) 0.1-100,000 ng/mL, (iii) a thickener, selected from hydroxyethyl cellulose, Karaya gum, a cationic **polyacrylamide** compd., and a sodium CM-cellulose 20-150 mg/mL, optionally a preservative and a dispersant, and (iv) the remaining is water, saline or a buffer soln.

IT **106096-92-8P**, Acidic fibroblast growth factor **106096-93-9P**, Basic fibroblast growth factor
RL: PEP (Physical, engineering or chemical process); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(pectic substances for stabilization of **heparin**-binding proteins and growth factors)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:380339 HCAPLUS
DOCUMENT NUMBER: 134:371845
TITLE: In situ crosslinking of proteins for **wound** sealant
INVENTOR(S): Miller, Douglas R.; Tizard, Ian R.; Keeton, Jimmy T.; Prochaska, Jerry F.
PATENT ASSIGNEE(S): The Texas A + M University System, USA
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001035882	A1	20010525	WO 2000-US31450	20001115

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,

CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165567P P 19991115
US 1999-166024P P 19991117

AB This invention relates to materials and methods for in situ crosslinking of proteins, including collagen, with peroxidase, including horseradish peroxidase, and H2O2 to form biocompatible semi-solid gels useful in a no. of biol. and food product applications. The mixt. applied to the **wound** sealing further comprises at least one addnl. agent selected from the group consisting of proteins, vaccine antigens, adjuvants, growth factors, microbeads and drugs, such as antimicrobials. The protein addnl. agent is selected from the group consisting of bovine serum albumin, fibrinogen, fibronectin, fibroblast growth factor, and human placental hyaluronic acid. A method of forming a semisolid crosslinked polymer on the surface of meat or poultry tissues for use as a food binding/restructuring agent comprises the steps of crosslinking a protein with a peroxidase in the presence of peroxide. Also, a method for growing dermal fibroblasts in vitro comprises the steps of growing the fibroblasts in a peroxide crosslinked collagen polymer.

IT **106096-93-9**, Basic fibroblast growth factor
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peroxidase and H2O2 for in situ crosslinking of proteins including collagen for tissue sealant)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:861512 HCAPLUS
DOCUMENT NUMBER: 134:32938
TITLE: Keratinocyte Growth Factor-2 formulations
INVENTOR(S): Gentz, Reiner L.; Chopra, Arvind; Kaushal, Parveen; Spitznagel, Thomas; Unsworth, Edward; Khan, Fazal
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000072872	A1	20001207	WO 2000-US15186	20000602

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,

ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-137448P P 19990602
US 1999-160913P P 19991022

AB The invention is directed to liq. and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivs. thereof. This invention further relates to the formulations of KGF-2 for therapeutic use, for example, to promote or accelerate **wound** healing.

IT **9005-49-6, Heparin**, biological studies
RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(keratinocyte growth factor-2 formulations for promotion of **wound** healing)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:271858 HCAPLUS
DOCUMENT NUMBER: 132:313737
TITLE: Preparation of supplemented and unsupplemented tissue sealants
INVENTOR(S): MacPhee, Martin James; Drohan, William Nash; Woolverton, Christoper J.
PATENT ASSIGNEE(S): The American National Red Cross, USA
SOURCE: U.S., 79 pp., Cont.-in-part of U.S. Ser. No. 351,006, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6054122	A	20000425	US 1995-479034	19950607
EP 1142581	A2	20011010	EP 2001-113651	19911127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2223889	AA	19961219	CA 1996-2223889	19960607
WO 9640174	A1	19961219	WO 1996-US10006	19960607
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9661698	A1	19961230	AU 1996-61698	19960607
EP 869804	A1	19981014	EP 1996-919340	19960607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11507277	T2	19990629	JP 1996-502147	19960607
AU 9884192	A1	19981105	AU 1998-84192	19980911
AU 733471	B2	20010517		

PRIORITY APPLN. INFO.: US 1990-618419 B2 19901127
US 1991-798919 B2 19911127
US 1993-31164 B1 19930312

US 1994-328552	B2	19941025
US 1994-351006	B2	19941207
EP 1992-901268	A3	19911127
AU 1994-63648	A3	19940314
US 1995-474078	A	19950607
US 1995-479034	A	19950607
WO 1996-US10006	W	19960607

AB A fibrin sealant **dressing** may be supplemented with at least 1 compn. selected from, e.g., 1 or more regulatory compds., antibody, antimicrobial compns., analgesics, anticoagulants, antiproliferatives, anti-inflammatory compds., cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of prepg. and/or using the unsupplemented or supplemented fibrin sealant **dressing**. An 800-mL culture of recombinant E. coli contg. a plasmid that included DNA encoding HBGF-1.beta. was prepd. After induction and culturing for 24 h at 37.degree. the cells were centrifuged and the supernatant was discarded. He cell pellet was resuspended in 25 mls of 20 mM phosphate buffer, contg. pH 7.3 0.15M NaCl. The suspended cells were disrupted with a cell disrupter and the cell debris was sepd. from the resulting soln. by centrifugation at 5000 G for 20 min. The pellet was discarded and the supernatant contg. the solubilized HBGF-1.beta. and other bacterial proteins was loaded onto column of **heparin**-Sepharose. Three peaks of UV absorbing material eluted and were analyzed by SDS **polyacrylamide** gel electrophoresis. Peak no. 3 was subjected to electrophoresis as a single band at about 17,400 daltons and contained substantially pure HBGF-1.beta.. Peak no. 3 which contained the growth factor activity, was dialyzed overnight against 20 mM histidine and pH 7.5 0.15M NaCl. This purified HBGF-1 was used to supplement FG in subsequent examples.

IT **106096-92-8 106096-93-9**, Fibroblast growth factor-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of supplemented and unsupplemented tissue sealants)

REFERENCE COUNT: 225 THERE ARE 225 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:425765 HCAPLUS
DOCUMENT NUMBER: 131:78442
TITLE: Keratinocyte growth factor-2 formulations for promotion of **wound** healing
INVENTOR(S): Gentz, Reiner L.; Chopra, Arvind; Kaushal, Parveen; Spitznagel, Thomas; Unsworth, Edward; Khan, Fazal
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932135	A1	19990701	WO 1998-US26085	19981222
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9919057	A1	19990712	AU 1999-19057	19981222
EP 1041996	A1	20001011	EP 1998-963812	19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6238888	B1	20010529	US 1998-218444	19981222
JP 2001526239	T2	20011218	JP 2000-525126	19981222
US 2002016295	A1	20020207	US 2001-853666	20010514

PRIORITY APPLN. INFO.:
US 1997-68493P P 19971222
US 1998-218444 A1 19981222
WO 1998-US26085 W 19981222

AB The invention is directed to liq. and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivs. thereof. This invention further relates to the formulation of KGF-2 for therapeutic use, for example, to promote or accelerate **wound** healing.

IT **9005-49-6, Heparin,** biological studies
RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(gelling agent; keratinocyte growth factor-2 formulations for promotion of **wound** healing)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:350613 HCAPLUS
DOCUMENT NUMBER: 130:357215
TITLE: Improved **wound dressing** device and methods
INVENTOR(S): Gibbins, Bruce L.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925395	A2	19990527	WO 1998-US24272	19981113
WO 9925395	A3	19990812		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9916991	A1	19990607	AU 1999-16991	19981113
EP 1030695	A2	20000830	EP 1998-961733	19981113

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

PRIORITY APPLN. INFO.: US 1997-971074 A2 19971114
WO 1998-US24272 W 19981113

AB The present invention comprises methods and compns. for treating **wounds**. More particularly, the present invention comprises methods and compns. for **wound dressing** devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide having active agents, such as **wound** healing agents, incorporated therein. The matrix may be formed into any desired shape for treatment of **wounds**. A mixing tank was charged with 161.4 kg water and 9.1894 kg acrylamide, and 0.10347 kg of methylenebisacrylamide and 9.3046 kg glycerol were added and mixed. Then, 1.0213 kg guar gum was dispersed in a mixt. contg. 0.9770 kg isopropanol and 2 kg water. The soln. of guar gum was dispersed into the acrylamide mixt. After suitable mixing, 0.1042 kg TEMED was added and polymn. was catalyzed with 0.0999 kg ammonium persulfate. While the batch was still liq., it was poured into molds to form sheets. After gelling had occurred, sheets were transferred to a desiccator and dehydrated to form a stable sheet.

IT **106096-92-8**, Acidic fibroblast growth factor **106096-93-9**, Basic fibroblast growth factor
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**wound dressings** contg. polymer network and polysaccharides and active agents)

L7 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1993:644381 HCAPLUS
DOCUMENT NUMBER: 119:244381
TITLE: Immobilization of chemical species in crosslinked matrices by crosslinking via latent reactive groups
INVENTOR(S): Swan, Dale Gustaf; Josephson, Mark William; Swanson, Melvin John
PATENT ASSIGNEE(S): Bio-Metric Systems, Inc., USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9316176	A1	19930819	WO 1993-US1248	19930211

W: AU, CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

CA 2107683	AA	19930814	CA 1993-2107683	19930211
AU 9336646	A1	19930903	AU 1993-36646	19930211
EP 585436	A1	19940309	EP 1993-905897	19930211
EP 585436	B1	20000503		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

JP 06506959	T2	19940804	JP 1993-514292	19930211
ES 2145044	T3	20000701	ES 1993-905897	19930211
US 5563056	A	19961008	US 1995-395521	19950227
AU 9714827	A1	19970626	AU 1997-14827	19970219
AU 716543	B2	20000224		

PRIORITY APPLN. INFO.:	US 1992-835206	A	19920213
	WO 1993-US1248	A	19930211
	US 1994-193904	B1	19940209

AB Chems., esp. pharmaceutically useful materials are immobilized in a crosslinked three dimensional matrix by first forming the matrix and enclosing the immobilized material and then activating latent reactive groups in the matrix to immobilize the compd. of interest. The method is particularly useful for coating important surfaces of medical goods such as **dressings** or blood bags. The preferred form of activation is by photoactivation. Photoactivatable **polyacrylamide** (PhotoPAA) was prepd. by the reaction of **polyacrylamide** and benzoylbensoyl chloride in CHCl3. **Heparin** was immobilized on regenerated polysulfone hollow fiber dialysis membranes using adsorption, photoimmobilization, or by coimmobilaztion with PhotoPAA. After washing of the membranes, the membranes to which **heparin** had been adsorbed carried 2.4 Factor Xa inhibition milliunits/cm2. For photoactivatable **heparin** this value was 5.8, and for the coimmobilized **heparin** it was 5.2. Further uses in cell culture and blood collection are demonstrated.

IT **9005-49-6, Heparin**, biological studies
RL: PROC (Process)
(immobilization of, in crosslinked matrix carrying photoactivatable reactive groups)

IT **9005-49-6DP, Heparin**, reaction products with N-(p-benzoyl)aminocapryloxysuccinimide
RL: PREP (Preparation)
(prepn. of, as photoactivatable **heparin** for immobilization)

L7 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	1990:11911 HCAPLUS
DOCUMENT NUMBER:	112:11911
TITLE:	Gel formulation containing polypeptide growth factors
INVENTOR(S):	Finkenaur, Amy L.; Cohen, Jonathan M.; Shalaby, Shalaby W.; Sandoval, Elisabeth A.; Bezwada, Rao S.; Kronenthal, Richard L.
PATENT ASSIGNEE(S):	Ethicon, Inc., USA
SOURCE:	Eur. Pat. Appl., 16 pp. CODEN: EPXXDW
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	4
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 312208	A1	19890419	EP 1988-308574	19880916
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
AU 8822235	A1	19890323	AU 1988-22235	19880914
JP 02000112	A2	19900105	JP 1988-232102	19880916
ZA 8806947	A	19900530	ZA 1988-6947	19880916
PRIORITY APPLN. INFO.:			US 1987-98816 A	19870918
			US 1988-233483 A	19880819

AB Gel formulations contain polypeptide growth factors having human mitogenic or angiogenic activity and water sol. polymers for providing viscosities within various ranges detd. by the application of the gels. These gel formulations are useful for topical or incisional **wound** healing fur cutaneous **wounds**, in the anterior chamber of the eye and other ophthalmic **wound** healing. These formulations provide controlled release and increased contact time of the growth factor to the **wound** site. Thus, 6.3 g methylparaben, 0.7 g propylparaben, and 177.5 g mannitol was dissolved in 3500 mL water and to this soln. was added 17.5 g powd. poly(acrylic acid) (Carbopol 940) with mixing at 1000 rpm. The soln. was neutralized with 10% NaOH and 900 g resultant gel was removed and autoclaved, followed by addn. of 12 mL sterile EGF (1.18 mg/mL) to give a sterile gel (viscosity 490,000-520,000 cps) contg. 15.6 .mu.g EGF/mL. This gel gave an enhanced rate and quality of sound healing in pig and guinea pig partial thickness skin excision models.

IT **9005-49-6**, **Heparin**, biological studies
RL: BIOL (Biological study)
(aq. gels contg. polypeptide growth factors and)

IT **106096-92-8**, Acidic fibroblast growth factor **106096-93-9**, Basic fibroblast growth factor
RL: BIOL (Biological study)
(aq. gels contg. viscosity-enhancing polymers and, for healing of cutaneous and ophthalmic **wounds**)

L7 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	1981:71410 HCAPLUS
DOCUMENT NUMBER:	94:71410
TITLE:	Hemolytic properties of special materials exposed to a shear flow, and plasma changes with shear
AUTHOR(S):	Monroe, Joseph M.; Lijana, Robert C.; Williams, Michael C.
CORPORATE SOURCE:	Chem. Eng. Dep., Univ. California, Berkeley, CA, 94720, USA
SOURCE:	Biomater., Med. Devices, Artif. Organs (1980), 8(2), 103-44 CODEN: BMDOAI; ISSN: 0090-5488
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB Three types of materials were evaluated for their tendency to induce hemolysis when exposed to a laminar blood flow between rotating parallel disks: (1) TDMAC-**heparinized** surfaces of polycarbonate (Lexan) silicone rubber, and poly(vinyl chloride); (2) **polyacrylamide** [9003-05-8] hydrogels (PAH) prepd. by 3 different chem. processes; and (3) fluorinated ethylcellulose (FEC). All were compared to a polyethylene

(PE) std., to normalize data for variations in blood quality. Multiple tests, showing good reproducibility, demonstrated: FEC is a very low hemolyzer, about 60% of PE; the PAH surfaces are poorer than PE, giving 120-220% of PE hemolysis depending on fabrication and shipment history; and TDMAC-**heparinized** surfaces are highly hemolytic, in the range 160-440% of PE depending on substrate. Plastics used as substrates for the coatings cited above were also evaluated: Delrin, Lexan, Nylon 6, polypropylene, and a polyether urethane. Tentative explanations are advanced for hemolytic variations, in terms of surface chem. and material interactions with the blood.